logo
Select company
Select metric
45.03%Cash to Assets Ratio
VS
Market
90
Sector
69
Industry
57
History
52
$ 16.95Close
$ 3.93 - $ 21.42 52-Week Range
Ticker Information

Ticker

URGN

Company Name

UROGEN PHARMA LTD

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

UROGEN PHARMA LTD - Cash to Assets Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

URGN - Cash to Assets Historical data
DateTotal AssetsCash and EquivalentsCash to Assets Ratio
6/30/2025$ 208.72M$ 93.99M45.03%
3/31/2025$ 247.62M$ 105.11M42.45%
12/31/2024$ 285.71M$ 173.06M60.57%
9/30/2024$ 301.94M$ 125.99M41.73%
6/30/2024$ 281.85M$ 220.8M78.34%
3/31/2024$ 200.57M$ 132.26M65.94%
12/31/2023$ 178.31M$ 95.82M53.74%
9/30/2023$ 193.63M$ 120.12M62.04%
6/30/2023$ 95.36M$ 20.94M21.96%
3/31/2023$ 112.95M$ 37.35M33.07%
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • UROGEN PHARMA LTD's latest trailing twelve months (TTM) Cash to Assets stands at 18.43%.
  • Over the past 5 years, UROGEN PHARMA LTD's average Cash to Assets has been 45.83%.
  • The median Cash to Assets for UROGEN PHARMA LTD during this period was 42.64%
  • UROGEN PHARMA LTD reached its highest Cash to Assets over the past 5 years at 78.34%.
  • The lowest Cash to Assets recorded by UROGEN PHARMA LTD in the same timeframe 18.43%

UROGEN PHARMA LTD's Cash to Assets vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash to Assets Benchmarks
CompanyCash to Assets
NRIX : NURIX THERAPEUTICS INC 15.2%SNDX : SYNDAX PHARMACEUTICALS INC 18.26%GYRE : GYRE THERAPEUTICS INC 23.91%CRMD : CORMEDIX INC 63.07%NAGE : NIAGEN BIOSCIENCE INC 66.07%ZYME : ZYMEWORKS INC 24.06%PHAT : PHATHOM PHARMACEUTICALS INC 60.92%TBPH : THERAVANCE BIOPHARMA INC 66.37%WVE : WAVE LIFE SCIENCES LTD 82.61%KURA : KURA ONCOLOGY INC 12.01%

Definition of Cash to Assets Ratio

[Calculation] The Cash to Assets Ratio expresses a company’s cash and cash equivalents [CashnEq] as a percentage of total [Assets].
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for UROGEN PHARMA LTD is calculated as follows: CashnEq [ $ 25.79M ] / Assets [ $ 139.89M ]
(=) Cash to Assets [ 18.43% ]

URGN - Cash to Assets Ratio, Last 5 years

18.43%

Minimum

Sep 30, 2020

78.34%

Maximum

Jun 30, 2024

45.83%

Average

42.64%

Median

Cash to Assets Benchmark Analysis

The chart above depicts the distribution of Cash to Assets for companies in the Total Stock Market. The average Cash to Assets of the companies is 9.84% with a standard deviation of 9.62%.
The following table provides additional summary stats:
Cash to Assets in the Market:
filtered constituents3.95K
min0%
max40.92%
average9.84%
median6.44%
std9.62%